English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Point-of-care Molecular Diagnostics Market Outlook (2023 to 2033)
The Global Point-of-care Molecular Diagnostics Industry is on track for a significant surge, fueled by the increasing demand for faster and more convenient diagnostic solutions. According to a recent analysis by Future Market Insights (FMI), the market is projected to reach an impressive US$11.1 billion by 2033, reflecting a remarkable growth trajectory from its estimated valuation of US$4.4 billion in 2023. This phenomenal rise signifies a Compound Annual Growth Rate (CAGR) of 9.7% over the next decade, highlighting the growing adoption of point-of-care molecular diagnostics across various healthcare settings.
The escalating prevalence of infectious and chronic diseases, encompassing cardiovascular ailments, diabetes, and the ongoing challenges posed by COVID-19, is driving a surge in the adoption of point-of-care molecular diagnostics. In response to the critical need for timely and cost-effective testing, the market is witnessing an unprecedented demand for these advanced diagnostics solutions.
Request a Sample of this Report Now Use Work Email To Get Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-14279
The growing advanced technology, diagnostic tests, preventive medicine, and knowledge of molecular mechanisms are driving the market growth. Furthermore, the adoption of point-of-care molecular diagnostics by laboratory specialists for sequencing DNA & multi-gene is expanding the market size. These diagnostics rapidly show the results with accuracy and are estimated to increase the sales of point-of-care molecular diagnostics.
Increasing respiratory, gastrointestinal, and sexually transmitted diseases are advancing the market growth. Emerging economies, government initiatives, and low-cost POC molecular diagnostics are the prime factors that propel market opportunities.
Factors Restraining the Market Growth
The market is going through a growth decline due to a few factors which are given below:
The dearth of consciousness about healthcare products, and poor penetration of advanced healthcare devices restrain market growth. The unavailability of advanced devices and the absence of government policies must gain market growth in developing countries.
Which Technology Category Booms the Market Growth?
The RT-PCR category dominates the global market with its remarkable CAGR of 9.2% during the foreseen time. The adoption of RT-PCR is rising due to the rise in tests such as genomics, COVID-19, proteomics, and others. It is a real-time system that shows results immediately, has high sensitivity, and costs efficiently. Due to the significant growth of infectious patients, healthcare providers are accelerating the demand for RT-PCR to provide patients with relevant data immediately.
Global Point-of-care Molecular Diagnostics Industry Key Takeaways:
The Global Point-of-care Molecular Diagnostics Industry is expected to have a valuation of US$ 11.1 billion by 2033.
With a CAGR of 9.7%, the global market increasing from 2022 to 2033.
The United States market is anticipated to capture a CAGR of 9.5% through 2033.
With a CAGR of 8.8%, the United Kingdom market significantly uplifts during the forecast period.
China’s market is expected to expand at a CAGR of 9.1% over the forecast period.
Japan’s market is likely to capture a CAGR of 8.2% from 2023 to 2033.
Who is winning?
Key players fragment the global market by contributing an impressive role. These players are bringing new ideas and adapting them to build advanced products, which in turn surging market opportunities. Growing technologies, including Artificial Intelligence and the Internet of Things, have surpassed market growth in recent years.
By accepting these technologies, key players welcome better detection machines and equipment as per patients’ requirements. They further follow several effective marketing strategies such as partnerships, mergers, acquisitions, agreements, and product launches.
Recent Developments in the Global Point-of-care Molecular Diagnostics Industry :
In Feb 2022, Sense Biodetection signed an agreement with Una Health to distribute COVID-19 testing equipment.
In Dec 2021, FIND Company invested a valuation of US$ 21 million in S.D. Biosensor, Biomeme, Quaife, and Bioneer for manufacturing, developing and launching an affordable COVID-19 testing detector.
A healthcare provider BioMérieux agreed to partner with Africa Medical Supplies Platform in Oct 2020 to supply premium quality COVID-19 diagnostic solutions.
Abbott Laboratories announced its new COVID-19 detection product which can deliver results within minutes, in March 2020.
In Oct 2018, QIAGEN agreed to enhance its portfolio with STAT-Dx to provide its customers with a next-generation PCR system.
Click Here To Purchase Your Full Report
https://www.futuremarketinsights.com/checkout/14279
Global Point-of-care Molecular Diagnostics Industry Segmentation by Category
By Products & Services:
Assays & Kits
Instruments &Analyzers
Software & Services
By Technology:
RT-PCR
INAAT
Other Technologies
By Application:
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End User:
Physicians’ Offices
Hospitals & ICUs
Research Institutes
Other End Users
The Global Point-of-care Molecular Diagnostics Industry is on track for a significant surge, fueled by the increasing demand for faster and more convenient diagnostic solutions. According to a recent analysis by Future Market Insights (FMI), the market is projected to reach an impressive US$11.1 billion by 2033, reflecting a remarkable growth trajectory from its estimated valuation of US$4.4 billion in 2023. This phenomenal rise signifies a Compound Annual Growth Rate (CAGR) of 9.7% over the next decade, highlighting the growing adoption of point-of-care molecular diagnostics across various healthcare settings.
The escalating prevalence of infectious and chronic diseases, encompassing cardiovascular ailments, diabetes, and the ongoing challenges posed by COVID-19, is driving a surge in the adoption of point-of-care molecular diagnostics. In response to the critical need for timely and cost-effective testing, the market is witnessing an unprecedented demand for these advanced diagnostics solutions.
Request a Sample of this Report Now Use Work Email To Get Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-14279
The growing advanced technology, diagnostic tests, preventive medicine, and knowledge of molecular mechanisms are driving the market growth. Furthermore, the adoption of point-of-care molecular diagnostics by laboratory specialists for sequencing DNA & multi-gene is expanding the market size. These diagnostics rapidly show the results with accuracy and are estimated to increase the sales of point-of-care molecular diagnostics.
Increasing respiratory, gastrointestinal, and sexually transmitted diseases are advancing the market growth. Emerging economies, government initiatives, and low-cost POC molecular diagnostics are the prime factors that propel market opportunities.
Factors Restraining the Market Growth
The market is going through a growth decline due to a few factors which are given below:
The dearth of consciousness about healthcare products, and poor penetration of advanced healthcare devices restrain market growth. The unavailability of advanced devices and the absence of government policies must gain market growth in developing countries.
Which Technology Category Booms the Market Growth?
The RT-PCR category dominates the global market with its remarkable CAGR of 9.2% during the foreseen time. The adoption of RT-PCR is rising due to the rise in tests such as genomics, COVID-19, proteomics, and others. It is a real-time system that shows results immediately, has high sensitivity, and costs efficiently. Due to the significant growth of infectious patients, healthcare providers are accelerating the demand for RT-PCR to provide patients with relevant data immediately.
Global Point-of-care Molecular Diagnostics Industry Key Takeaways:
The Global Point-of-care Molecular Diagnostics Industry is expected to have a valuation of US$ 11.1 billion by 2033.
With a CAGR of 9.7%, the global market increasing from 2022 to 2033.
The United States market is anticipated to capture a CAGR of 9.5% through 2033.
With a CAGR of 8.8%, the United Kingdom market significantly uplifts during the forecast period.
China’s market is expected to expand at a CAGR of 9.1% over the forecast period.
Japan’s market is likely to capture a CAGR of 8.2% from 2023 to 2033.
Who is winning?
Key players fragment the global market by contributing an impressive role. These players are bringing new ideas and adapting them to build advanced products, which in turn surging market opportunities. Growing technologies, including Artificial Intelligence and the Internet of Things, have surpassed market growth in recent years.
By accepting these technologies, key players welcome better detection machines and equipment as per patients’ requirements. They further follow several effective marketing strategies such as partnerships, mergers, acquisitions, agreements, and product launches.
Recent Developments in the Global Point-of-care Molecular Diagnostics Industry :
In Feb 2022, Sense Biodetection signed an agreement with Una Health to distribute COVID-19 testing equipment.
In Dec 2021, FIND Company invested a valuation of US$ 21 million in S.D. Biosensor, Biomeme, Quaife, and Bioneer for manufacturing, developing and launching an affordable COVID-19 testing detector.
A healthcare provider BioMérieux agreed to partner with Africa Medical Supplies Platform in Oct 2020 to supply premium quality COVID-19 diagnostic solutions.
Abbott Laboratories announced its new COVID-19 detection product which can deliver results within minutes, in March 2020.
In Oct 2018, QIAGEN agreed to enhance its portfolio with STAT-Dx to provide its customers with a next-generation PCR system.
Click Here To Purchase Your Full Report
https://www.futuremarketinsights.com/checkout/14279
Global Point-of-care Molecular Diagnostics Industry Segmentation by Category
By Products & Services:
Assays & Kits
Instruments &Analyzers
Software & Services
By Technology:
RT-PCR
INAAT
Other Technologies
By Application:
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End User:
Physicians’ Offices
Hospitals & ICUs
Research Institutes
Other End Users
Point-of-care Molecular Diagnostics Market Outlook (2023 to 2033)
The Global Point-of-care Molecular Diagnostics Industry is on track for a significant surge, fueled by the increasing demand for faster and more convenient diagnostic solutions. According to a recent analysis by Future Market Insights (FMI), the market is projected to reach an impressive US$11.1 billion by 2033, reflecting a remarkable growth trajectory from its estimated valuation of US$4.4 billion in 2023. This phenomenal rise signifies a Compound Annual Growth Rate (CAGR) of 9.7% over the next decade, highlighting the growing adoption of point-of-care molecular diagnostics across various healthcare settings.
The escalating prevalence of infectious and chronic diseases, encompassing cardiovascular ailments, diabetes, and the ongoing challenges posed by COVID-19, is driving a surge in the adoption of point-of-care molecular diagnostics. In response to the critical need for timely and cost-effective testing, the market is witnessing an unprecedented demand for these advanced diagnostics solutions.
Request a Sample of this Report Now Use Work Email To Get Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-14279
The growing advanced technology, diagnostic tests, preventive medicine, and knowledge of molecular mechanisms are driving the market growth. Furthermore, the adoption of point-of-care molecular diagnostics by laboratory specialists for sequencing DNA & multi-gene is expanding the market size. These diagnostics rapidly show the results with accuracy and are estimated to increase the sales of point-of-care molecular diagnostics.
Increasing respiratory, gastrointestinal, and sexually transmitted diseases are advancing the market growth. Emerging economies, government initiatives, and low-cost POC molecular diagnostics are the prime factors that propel market opportunities.
Factors Restraining the Market Growth
The market is going through a growth decline due to a few factors which are given below:
The dearth of consciousness about healthcare products, and poor penetration of advanced healthcare devices restrain market growth. The unavailability of advanced devices and the absence of government policies must gain market growth in developing countries.
Which Technology Category Booms the Market Growth?
The RT-PCR category dominates the global market with its remarkable CAGR of 9.2% during the foreseen time. The adoption of RT-PCR is rising due to the rise in tests such as genomics, COVID-19, proteomics, and others. It is a real-time system that shows results immediately, has high sensitivity, and costs efficiently. Due to the significant growth of infectious patients, healthcare providers are accelerating the demand for RT-PCR to provide patients with relevant data immediately.
Global Point-of-care Molecular Diagnostics Industry Key Takeaways:
The Global Point-of-care Molecular Diagnostics Industry is expected to have a valuation of US$ 11.1 billion by 2033.
With a CAGR of 9.7%, the global market increasing from 2022 to 2033.
The United States market is anticipated to capture a CAGR of 9.5% through 2033.
With a CAGR of 8.8%, the United Kingdom market significantly uplifts during the forecast period.
China’s market is expected to expand at a CAGR of 9.1% over the forecast period.
Japan’s market is likely to capture a CAGR of 8.2% from 2023 to 2033.
Who is winning?
Key players fragment the global market by contributing an impressive role. These players are bringing new ideas and adapting them to build advanced products, which in turn surging market opportunities. Growing technologies, including Artificial Intelligence and the Internet of Things, have surpassed market growth in recent years.
By accepting these technologies, key players welcome better detection machines and equipment as per patients’ requirements. They further follow several effective marketing strategies such as partnerships, mergers, acquisitions, agreements, and product launches.
Recent Developments in the Global Point-of-care Molecular Diagnostics Industry :
In Feb 2022, Sense Biodetection signed an agreement with Una Health to distribute COVID-19 testing equipment.
In Dec 2021, FIND Company invested a valuation of US$ 21 million in S.D. Biosensor, Biomeme, Quaife, and Bioneer for manufacturing, developing and launching an affordable COVID-19 testing detector.
A healthcare provider BioMérieux agreed to partner with Africa Medical Supplies Platform in Oct 2020 to supply premium quality COVID-19 diagnostic solutions.
Abbott Laboratories announced its new COVID-19 detection product which can deliver results within minutes, in March 2020.
In Oct 2018, QIAGEN agreed to enhance its portfolio with STAT-Dx to provide its customers with a next-generation PCR system.
Click Here To Purchase Your Full Report
https://www.futuremarketinsights.com/checkout/14279
Global Point-of-care Molecular Diagnostics Industry Segmentation by Category
By Products & Services:
Assays & Kits
Instruments &Analyzers
Software & Services
By Technology:
RT-PCR
INAAT
Other Technologies
By Application:
Respiratory Diseases
Sexually Transmitted Diseases
Hospital-acquired Infections
Cancer
Hepatitis
Gastrointestinal Disorders
Other Applications
By End User:
Physicians’ Offices
Hospitals & ICUs
Research Institutes
Other End Users
·102 Views
